Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real‐world analysis from the Chinese Myeloma Committee

We analysed 1384 newly diagnosed multiple myeloma patients from 10 representative centres of the Chinese Myeloma Committee to provide an important modern real-world reference. Survival outcomes were verified by the National Mortality Surveillance System to ensure data accuracy. The median age was 62 years, confirming a younger age at onset in Chinese patients than in Western populations. Treatment patterns have evolved significantly: Lenalidomide, bortezomib and dexamethasone (RVD) became the predominant induction regimen (51.8%), and upfront autologous haematopoietic stem cell transplantation (AHSCT) rates in patients aged ≤65 years rose to 40.0% (vs. 20.0% in our previous multicentre study). In a subcohort of patients from two out of the 10 sites, the median progression-free survival was 44.2 months. In the overall multicentre cohort, the median survival was not reached during a median follow-up of 46.6 months, with an estimated 4-year survival rate of 66.4%. Using the 2025 International Myeloma Society (IMS) / International Myeloma Working Group (IMWG) Consensus Genomic Staging (CGS), 26.2% of patients were classified as high risk. Patients harbouring ≥2 CGS high-risk factors (3.8%) had significantly inferior prognosis. This study validates the 2025 CGS in an Asian cohort and suggests that the widespread adoption of modern triplets is associated with improved real-world survival, while highlighting the distinct poor outcomes in patients with multiple CGS risk factors.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2026-07-26
DOI
https://doi.org/10.1111/bjh.70712
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real‐world analysis from the Chinese Myeloma Committee

Lifen Kuang, Zhongqing Li, Jin Lu, Chunrui Li et al.
British Journal of Haematology
Multiple Myeloma Research and Treatments
article

Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real‐world analysis from the Chinese Myeloma Committee

Lifen Kuang, Zhongqing Li, Jin Lu, Chunrui Li, Jia Song, Aijun Liao, Juan Du, Yuping Zhong, Maigeng Zhou, Jinlei Qi, Sinan Gu, Liru Wang, Juan Li, Rong Fu, Xuelin Dou, Ling Qin, Jun Luo, Lei Wen, Nan Peng, Yang Liu
article en

Abstract

We analysed 1384 newly diagnosed multiple myeloma patients from 10 representative centres of the Chinese Myeloma Committee to provide an important modern real-world reference. Survival outcomes were verified by the National Mortality Surveillance System to ensure data accuracy. The median age was 62 years, confirming a younger age at onset in Chinese patients than in Western populations. Treatment patterns have evolved significantly: Lenalidomide, bortezomib and dexamethasone (RVD) became the predominant induction regimen (51.8%), and upfront autologous haematopoietic stem cell transplantation (AHSCT) rates in patients aged ≤65 years rose to 40.0% (vs. 20.0% in our previous multicentre study). In a subcohort of patients from two out of the 10 sites, the median progression-free survival was 44.2 months. In the overall multicentre cohort, the median survival was not reached during a median follow-up of 46.6 months, with an estimated 4-year survival rate of 66.4%. Using the 2025 International Myeloma Society (IMS) / International Myeloma Working Group (IMWG) Consensus Genomic Staging (CGS), 26.2% of patients were classified as high risk. Patients harbouring ≥2 CGS high-risk factors (3.8%) had significantly inferior prognosis. This study validates the 2025 CGS in an Asian cohort and suggests that the widespread adoption of modern triplets is associated with improved real-world survival, while highlighting the distinct poor outcomes in patients with multiple CGS risk factors.

British Journal of Haematology
Qingdao University (CN), Sun Yat-sen University (CN), Guangxi Medical University (CN), Capital Medical University (CN), Peking University (CN), Tianjin Medical University General Hospital (CN), Shanghai Changzheng Hospital (CN), National Center for Chronic and Noncommunicable Disease Control and Prevention (CN), Qingdao Municipal Hospital (CN), Peking University People's Hospital (CN), First Affiliated Hospital of GuangXi Medical University (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), First Affiliated Hospital of Henan University of Science and Technology (CN), Tongji Hospital (CN), Huazhong University of Science and Technology (CN), China Medical University (CN)
National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation
Good health and well-being
Openalex Percentile: Top 9%
Multiple Myeloma Research and Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.